Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leppik, I. E.
Right arrow Articles by Turlapaty, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leppik, I. E.
Right arrow Articles by Turlapaty, P.
NEUROLOGY 1990;40:456
© 1990 American Academy of Neurology

Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients

I. E. Leppik, MD, B. A. Boucher, B. J. Wilder, MD, V. S. Murthy, MD, PhD, C. Watridge, MD, N. M. Graves, Pharm D, R. J. Rangel, MD, C. A. Rask, MD and P. Turlapaty, PhD

Department of Neurology (Drs. Leppik and Rask), University of Minnesota and MINCEP Epilepsy Care, P.A.; College of Pharmacy (Drs. Graves and Leppik), University of Minnesota, Minneapolis, MN; Colleges of Pharmacy and Medicine (Drs. Boucher and Watridge), University of Tennessee, Memphis, TN Department of Neurology (Drs. Wilder and Rangel), University of Florida, Gainesville, FL; Department of Medicine (Dr. Murthy), Samaritan Hospital Center, Milwaukee, WI; and DuPont Critical Care (Dr. Turlapaty), Chicago, IL.

ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phos-phatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.

Address correspondence and reprint requests to Dr. Ilo E. Leppik, Epilepsy Research Center, University of Minnesota, 2701 University Avenue, S.E., Suite 201, Minneapolis, MN 55414.

Supported by a grant from DuPont Critical Care.

Received May 22, 1989. Accepted for publication in final form August 31,1989.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by AAN Enterprises, Inc.